Thyroid screening (thyroid-stimulating hormone [TSH] and thyroid peroxidase [TPO]-antibodies) is recommended in women with RPL (Rao et al., 2008; van den Boogaard et al., 2011).	Strong ⊕⊕⊕○
Abnormal thyroid-stimulating hormone (TSH) and thyroid peroxidase [TPO]-antibody levels should be followed up by thyroxine (T4) testing in women with RPL (van den Boogaard et al., 2011; Lazarus et al., 2014).	Strong ⊕⊕⊕○
Assessment of polycystic ovary syndrome (PCOS), fasting insulin and fasting glucose is not recommended in women with RPL to improve next pregnancy prognosis (Rai et al., 2000; Craig et al., 2002; Wang et al., 2011; Maryam et al., 2012; Chakraborty et al., 2013; Ispasoiu et al., 2013; Kazerooni et al., 2013).	Strong ⊕⊕○○
Prolactin testing is not recommended in women with RPL in the absence of clinical symptoms of hyperprolactinemia (oligo/amenorrhoea) (Bussen et al., 1999) (Triggianese et al., 2015) (Li et al., 2013).	Conditional ⊕⊕○○
Ovarian reserve testing is not routinely recommended in women with RPL (Bussen et al., 1999; Hofmann et al., 2000; Prakash et al., 2006; Atasever et al., 2016).	Strong ⊕⊕○○
Luteal phase insufficiency testing is not recommended in women with RPL (Balasch et al., 1986; Jordan et al., 1994; Stephenson, 1996; Ogasawara et al., 1997; Badawy and Westpfal, 2000; Li et al., 2000).	Strong ⊕⊕○○
Androgen testing is not recommended in women with RPL (Watson et al., 1993; Okon et al., 1998; Rai et al., 2000; Nardo et al., 2002; Cocksedge et al., 2008; Kazerooni et al., 2013).	Strong ⊕⊕○○
LH testing is not routinely recommended in women with RPL (Sagle et al., 1988; Regan et al., 1990; Carp et al., 1995; Rai et al., 2000; Prakash et al., 2006; Kazerooni et al., 2013).	Strong ⊕○○○
Measurement of homocysteine plasma levels is not routinely recommended in women with RPL (Nelen et al., 2000; Alonso et al., 2002; Zammiti et al., 2008; Creus et al., 2013; Puri et al., 2013; Lee et al., 2016).	Strong ⊕○○○